Though our studies demonstrated that bleomycin-induced lung injury in mSTING mice actually improved after PD-L1 antibody treatment, this will be an ongoing point of safety monitoring in any future clinical trial designs targeted for patients with Group 3 PH, especially those with IPF. This evidence concerns the gene CD274 and idiopathic pulmonary fibrosis.